ResearchEnergy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.
Glucagon-like peptide-1 receptor agonist (GLP-1RA)-associated rapid weight loss may be accompanied by facial changes resembling accelerated aging, colloquially termed "Ozempic face". In this review, this proposed phenotype is termed GLP-1RA-associated facial accelerated aging (GLP-1RA-FAA) and is characterized primarily by facial volume loss and skin laxity, with possible but incompletely characterized alterations in dermal-adipose support, adipose-derived stem-cell biology, fibroblast-extracellular-matrix homeostasis, and facial muscle. Demand for energy-based device (EBD) treatment in this population is increasing; however, whether conventional EBD parameters are effective or safe in medication-associated facial volume depletion is unknown. A narrative review was informed by structured searches of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from January 2000 through August 31, 2026. Evidence was selected for clinical directness and relevance to radiofrequency, high-intensity focused ultrasound, broadband light, microwave, extracorporeal shock wave therapy, diode laser, and synchronized radiofrequency with high-intensity facial electrical stimulation. Available modalities differ in their intended tissue depth and in the potential relevance of three conceptual targets: preservation of adipose tissue, dermal fibroblast-extracellular-matrix remodeling, and facial muscle-SMAS support. Preclinical body-contouring studies suggest that sustained subcutaneous heating in the approximate 43-45°C range can be associated with adipocyte injury or apoptosis; however, no facial thermal dose threshold has been established, particularly in GLP-1RA-treated patients. No individual EBD modality has demonstrated simultaneous restoration of adipose, dermal, and muscle-related targets in prospective GLP-1RA-specific studies. Conservative control of treatment depth, careful avoidance of unnecessary deep energy deposition in volume-depleted regions, investigation of low-intensity dermal remodeling strategies, and evaluation of muscle-targeting approaches are proposed as research considerations. These concepts are hypothesis generating and do not constitute clinical recommendations or standards of care. Prospective controlled studies in well-characterized GLP-1RA-treated populations are required before device-specific protocols can be adopted. Medications used for weight management, including semaglutide (Ozempic® and Wegovy®) and tirzepatide (Mounjaro® and Zepbound®), can be associated with noticeable facial changes, particularly after substantial or rapid weight loss. These changes are often referred to informally in relation to specific medication brands, although they are not specific to one medication and may occur with medication-driven weight loss more broadly. Facial volume loss, looser skin, hollowing of the cheeks or temples, and a more tired or gaunt appearance may result mainly from loss of facial fat and other soft-tissue support. Whether these medications also affect the cells that maintain skin structure or facial muscles is still being studied. Energy-based devices are treatments that use controlled heat, light, ultrasound, or electrical stimulation. They are increasingly considered for skin tightening and facial rejuvenation. Different devices act at different tissue depths: some mainly affect the skin, whereas others may also reach deeper connective tissue, fat, or muscle. In people with medication-associated facial volume loss, deep or overly aggressive treatment may, in theory, affect already reduced fat layers or cause unwanted tissue injury. However, this possibility has not been adequately tested in people using GLP-1 receptor agonists or other weight-loss medications. This review examines the potential tissue targets, mechanisms, and available evidence for major energy-based technologies. It outlines cautious, research-oriented considerations, including careful control of treatment depth, conservative settings in thin or volume-depleted areas, and individualized assessment of whether muscle-targeting treatments may be appropriate. Direct clinical evidence in people with GLP-1RA-associated facial changes remains very limited. The approaches discussed in this review are early research considerations, not established treatment guidelines or standards of care.
